{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Furostilbestrol (diethylstilbestrol di(2-furoate)) is a synthetic estrogen that was first described in 1952. It is an ester of diethylstilbestrol (DES), a synthetic estrogen that was prescribed to pregnant women until 1971 to prevent miscarriages and that has been associated with cancer, birth defects and several other developmental abnormalities. Furostilbestrol was never marketed.
Status:
Investigational
Source:
INN:bentemazole [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Bentémazole was studied as an antifungal drug.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ACHIRAL)
Aronixil was developed as an anti-atherosclerotic drug.
Status:
Investigational
Source:
NCT01587911: Not Applicable Interventional Completed Lack of Satiety
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Ecabapide (DQ 2511) is a compound with antiulcer and gastroprokinetic activity. Evidence from basic studies in animal models suggests that the drug acts on peripheral mechanisms of neural control. In the stomach, ecabapide acts to suppress firing in vagal afferent nerves and thereby reduce the flow of sensory information into the dorsal vagal complex. The mechanism of action of ecabapide in suppressing discharge in vagal afferent terminals appears to mimic that of nitric oxide by stimulating formation of cGMP and activation of an inhibitory transduction cascade in the sensory fibres. In this respect the mechanism of its pro-kinetic action differs from other promoter agents. Ecabapide development has been discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Glypinamide is a part of the second-generation sulfonamide derivatives. Members of this group of compounds are used to control blood sugar levels in diabetes mellitus type 2.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Eclanamine is a nontricyclic antidepressant agent. Down-regulation of beta-adrenergic receptors in the cerebral cortex may be involved in mediating the eclanamine pharmacological effect.
Class (Stereo):
CHEMICAL (RACEMIC)
Ecastolol is a beta-sympatholytic agent.
Status:
Investigational
Source:
NCT04492956: Phase 2 Interventional Completed Childhood-Onset Fluency Disorder (Stuttering)
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ecopipam (SCH-39166) is a selective D1 dopamine receptor antagonist both in vitro and in vivo. Additionally, it exhibits saturable, high-affinity binding to D5 receptors. Ecopipam was studied clinically for a variety of indications, including schizophrenia, drug abuse, and obesity, but in each case undesirable effects were observed. Currently, ecopipam is in clinical trials for the treatment of Lesch-Nyhan and Gilles de la Tourette's syndromes.
